COVID-19急性期后内分泌随访:基于现有临床证据的实用建议
本文为内分泌学会(Endocr Pract)发布的实用建议,基于PubMed/MEDLINE文献综述,聚焦COVID-19急性期后内分泌随访。急性期观察到的生化内分泌异常多在恢复后改善;既往糖尿病患者应确保最佳血糖控制,年龄<70岁及需ICU入住者可于3个月筛查新发糖尿病;甲状腺功能异常与肾上腺功能不全通常随访中恢复正常,不推荐广泛筛查;垂体卒中与男性性腺功能减退罕见,按临床情况随访;低钙血症常见但无需常规复查血钙。建议旨在指导医师识别和管理急性期后内分泌后遗症。
要点
- 既往糖尿病患者在COVID-19后应确保最佳血糖控制。
- 年龄<70岁及需ICU入住的患者可在3个月时筛查新发糖尿病。
- 甲状腺功能异常(正常甲状腺病态综合征和非典型甲状腺炎)与肾上腺功能不全通常随访中恢复正常,不推荐COVID-19后广泛筛查。
- 垂体卒中和男性性腺功能减退在COVID-19中罕见,可按临床情况适当随访。
- COVID-19期间低钙血症不少见,但不推荐急性期后常规检测血钙。
适用人群与场景
- COVID-19急性期后患者的内分泌随访。
- 既往有糖尿病的患者;年龄<70岁及需ICU入住的患者为新发糖尿病筛查对象。
诊断标准与关键阈值
- 新发糖尿病筛查:年龄<70岁及需ICU入住的患者,于3个月时筛查。
处置流程与药物剂量
- 既往糖尿病患者在COVID-19后应确保最佳血糖控制。
- 年龄<70岁及需ICU入住的患者可于3个月时筛查新发糖尿病。
- 不推荐COVID-19急性期后广泛筛查甲状腺和肾上腺功能。
- 垂体卒中和男性性腺功能减退按临床情况适当随访。
- 不推荐COVID-19急性期后常规检测血清钙。
研究设计与关键结果
- COVID-19可导致新发高血糖/糖尿病或使既存糖尿病患者的血糖异常恶化。
- COVID-19急性期后新发糖尿病已有描述。
- COVID-19中已有甲状腺功能异常(正常甲状腺病态综合征和非典型甲状腺炎)和肾上腺功能不全的报道,但甲状腺/肾上腺功能通常在随访中恢复正常。
- 垂体卒中和男性性腺功能减退在COVID-19中罕见。
- COVID-19期间低钙血症不少见。
证据类型、等级与局限
- 证据类型:基于PubMed/MEDLINE文献综述的实用建议(指南/共识)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 临床医生应确保COVID-19后既往糖尿病患者的血糖控制达标。
- 对年龄<70岁及需ICU入住的患者,可考虑在3个月时筛查新发糖尿病。
- 不推荐对COVID-19急性期后患者广泛筛查甲状腺和肾上腺功能。
- 不推荐COVID-19急性期后常规检测血清钙。
指南或共识出处
- 指南名称:Endocrine Follow-up During Post-Acute COVID-19: Practical Recommendations Based on Available Clinical Evidence;发布机构:Endocrine Pract;年份:原文未给出。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: COVID-19 affects multiple endocrine organ systems during the disease course. However, follow-up data post-COVID-19 is scarce; hitherto available limited data suggest that most of the biochemical endocrine dysfunctions observed during acute phase of COVID-19 tend to improve after recovery. Hence, we aim to provide a rational approach toward endocrine follow-up of patients during post-acute COVID-19.
METHODS: We performed a literature review across PubMed/MEDLINE database looking into the effects of COVID-19 on endocrine system and subsequent long-term endocrine sequelae. Accordingly, we have presented a practical set of recommendations regarding endocrine follow-up post-acute COVID-19.
RESULTS: COVID-19 can lead to new-onset hyperglycemia/diabetes mellitus or worsening of dysglycemia in patients with preexisting diabetes mellitus. Hence, those with preexisting diabetes mellitus should ensure optimum glycemic control in the post-COVID-19 period. New-onset diabetes mellitus has been described post-acute COVID-19; hence, a selected group of patients (aged <70 years and those requiring intensive care unit admission) may be screened for the same at 3 months. Thyroid dysfunction (euthyroid sick syndrome and atypical thyroiditis) and adrenal insufficiency have been described in COVID-19; however, thyroid/adrenal functions usually normalize on follow-up; hence, widespread screening post-acute COVID-19 should not be recommended. Pituitary apoplexy and male hypogonadism have rarely been documented in COVID-19; therefore, appropriate follow-up may be undertaken as per clinical context. Hypocalcemia during COVID-19 is not uncommon; however, routine estimation of serum calcium post-COVID-19 is not warranted.
CONCLUSION: The recommendations herein provide a rational approach that would be expected to guide physicians to better delineate and manage the endocrine sequelae during post-acute COVID-19.
参考来源
- Pal R, Joshi A, Bhadada SK, et al. Endocrine Follow-up During Post-Acute COVID-19: Practical Recommendations Based on Available Clinical Evidence. Endocr Pract. 2022. PMID: 35158058. doi:10.1016/j.eprac.2022.02.003
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。